Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Maxcyte Inc
(NQ:
MXCT
)
4.250
+0.080 (+1.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Maxcyte Inc
< Previous
1
2
3
4
Next >
Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
May 11, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Sonos, Inc. (NASDAQ: SONO) shares dipped 25.2% to $15.82 in pre-market...
Via
Benzinga
Recap: MaxCyte Q1 Earnings
May 10, 2023
Via
Benzinga
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 10, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
May 04, 2023
Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases
From
MaxCyte, Inc
Via
GlobeNewswire
Looking Into MaxCyte's Return On Capital Employed
March 16, 2023
Via
Benzinga
MaxCyte's Earnings: A Preview
March 14, 2023
Via
Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
April 27, 2023
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical.
Via
InvestorPlace
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
April 12, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
March 31, 2023
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...
Via
Benzinga
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
March 27, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Earnings Perspective: Return On Capital Employed
December 14, 2022
Via
Benzinga
MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns
April 13, 2022
Via
Benzinga
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
March 08, 2023
MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
March 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023
February 22, 2023
For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards.
Via
InvestorPlace
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
February 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
January 03, 2023
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies
From
MaxCyte, Inc
Via
GlobeNewswire
7 Hot Stocks to Book Profits In Before 2023
December 19, 2022
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.
Via
InvestorPlace
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
December 05, 2022
Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology.
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2022 Financial Results
November 09, 2022
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Outlook For MaxCyte
November 08, 2022
MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will...
Via
Benzinga
MaxCyte to Participate in Upcoming Investor Conferences
November 02, 2022
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
October 12, 2022
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
September 28, 2022
MaxCyte Inc (NASDAQ: MXCT) has signed a
Via
Benzinga
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
September 28, 2022
From
MaxCyte, Inc
Via
GlobeNewswire
Recap: MaxCyte Q2 Earnings
August 10, 2022
MaxCyte (NASDAQ:MXCT) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings MaxCyte reported in-line EPS of...
Via
Benzinga
A Preview Of MaxCyte's Earnings
August 09, 2022
MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will...
Via
Benzinga
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.